Latest news with #eProteinDiscovery
Business Wire
28-05-2025
- Business
- Business Wire
Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
CAMBRIDGE, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera's eProtein Discovery System with Cytiva's Biacore™ surface plasmon resonance (SPR) technology. Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera's eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva's Biacore SPR system. Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: 'Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery's ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery's capability to streamline protein production workflows with Cytiva's Biacore protein characterization systems open a whole new avenue for accelerating drug development.' Anna Moberg, Senior Manager and Project Manager, Cytiva, added: 'The ability of Nuclera's eProtein Discovery to accelerate protein production and purification complements Cytiva's Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.' For more information about Nuclera's eProtein Discovery System, please visit:
Yahoo
28-05-2025
- Business
- Yahoo
Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
Collaboration combines Nuclera's eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva's Biacore SPR system, which characterizes molecular interactions Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton's Tyrosine Kinase, which is implicated in B-cell malignancies CAMBRIDGE, England & MARLBOROUGH, Mass., May 28, 2025--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a collaboration with Cytiva, a global life sciences leader. This collaboration is focused on accelerating the production, purification and characterization of proteins required for drug research and development, enabled through the combination of Nuclera's eProtein Discovery System with Cytiva's Biacore™ surface plasmon resonance (SPR) technology. Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera's eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva's Biacore SPR system. Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: "Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery's ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery's capability to streamline protein production workflows with Cytiva's Biacore protein characterization systems open a whole new avenue for accelerating drug development." Anna Moberg, Senior Manager and Project Manager, Cytiva, added: "The ability of Nuclera's eProtein Discovery to accelerate protein production and purification complements Cytiva's Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development." For more information about Nuclera's eProtein Discovery System, please visit: View source version on Contacts Media contact: Dr. Ben RutterZyme CommunicationsTel: +44(0)7920 770 935Email: Sign in to access your portfolio
Business Wire
06-05-2025
- Business
- Business Wire
Nuclera Establishes Distribution Network Across APAC and the Middle East
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, today announced that it has established a distribution network across APAC and the Middle East. Marking a key milestone in the Company's global commercial strategy, the expansion establishes new regional distribution networks, providing localized technical support for customers in these key markets. In response to the rapidly growing demand for its innovative eProtein Discovery System, Nuclera has formed partnerships with seven channel partners: MineBio Life Sciences Ltd (China), Kiko Tech Co.,Ltd (Japan), CHAYON Laboratories, Inc. (South Korea), Sciencewerke Pte Ltd (Singapore), Cold Spring Biotech (Taiwan) and Yair Or Technologies Ltd (Israel). These new partnerships follow the recent expansion of the eProtein Discovery System, which now enables discovery of both membrane and soluble proteins 1. Proteins represent 95% of drug targets designed to combat disease 2 therefore developing reliable and efficient methods to identify how to express soluble and active proteins of interest is a crucial aspect of the drug discovery process. Researchers are realizing the value of systems, such as eProtein Discovery, that streamline protein production and enable rapid, scalable access to high-quality proteins, across cell-free and cell-based expression methods. 'Expanding into APAC and the Middle East, in response to growing global demand, demonstrates the potential of eProtein Discovery to revolutionize the way proteins are made,' Said Dr Michael Chen, CEO and co-founder, Nuclera. 'Testament to the growing demand are installations of eProtein Discovery at leading pharma and academic institutions and the first installation of our System within a CRO. We have partnered with established partners across key markets to enable specialized local support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively.' Joseph Bertelsen, CCO, Nuclera, commented: 'We are excited to have extended our reach to the Middle East and Asia through partnering with key distributors Yair Or Technologies, Minebio, Chayon Laboratories, Kiko-Tech, ScienceWerke, and Cold Spring Biotech. Establishing these distribution channels supports our goal of global expansion and comes at a pivotal time for the Company as we are focused on ramping-up commercially following the successful close of our series C fundraising round.'
Yahoo
14-04-2025
- Business
- Yahoo
Nuclera Expands eProtein Discovery Capabilities to Enable Membrane Protein Production
Membrane proteins synthesized and purified within 48 hours. Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized CAMBRIDGE, England & BOSTON, April 14, 2025--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system. This expanded capability enables the expression, purification and stabilization of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free protein synthesis, digital microfluidics, and optimized additive screening, eProtein Discovery can express and purify functional, correctly folded membrane proteins, in 48 hours. Membrane proteins play vital roles in regulating cellular processes and many are implicated in the development and progression of disease. 60% of FDA-approved drugs target membrane proteins1 yet the extraction and stabilization of these structurally complex proteins remains challenging due to their intrinsic hydrophobic nature. Nuclera demonstrated the capabilities of eProtein Discovery to produce membrane proteins by synthesizing MsbA (a membrane transporter) and ZMPSTE24 (an integral membrane protein)2. In 24 hours, eProtein Discovery evaluated different expression and purification conditions, including assessing the effects of using nanodiscs, lipids and detergents, to identify the optimal conditions for producing soluble, stable MsbA and ZMPSTE24. Scale-up production of these membrane proteins was achieved within 48 hours, enabling rapid functional evaluation. MsbA and ZMPSTE24 generated using eProtein Discovery had high-yield, were functionally active, and compatible with cryo-Electron Microscopy (cryo-EM). Existing eProtein Discovery users can access this new membrane protein production capability through a software update. Dr Toby Ost, SVP of Product Development, Nuclera, said: "Membrane protein production has long been a technical challenge, often resulting in misfolded or inactive proteins. eProtein Discovery overcomes these challenges, enabling scientists to rapidly produce functional membrane proteins, accelerating drug discovery and structural biology workflows." Dr Konstantinos Beis, Reader in Membrane Protein Structural Biology, Imperial College London, added: "The eProtein Discovery System is a welcome new toolkit for membrane protein production. We were commissioned via Imperial Consultants to test the protein quality in our lab - and the early results are promising." For more information about Nuclera's eProtein Discovery system, please visit: Paper: How many drug targets are there? Poster: Functional Membrane Proteins - Ready in 48 Hours View source version on Contacts Media contact: Dr Ben RutterZyme CommunicationsTel: +44(0)7920 770 935Email: Sign in to access your portfolio
Yahoo
14-04-2025
- Business
- Yahoo
Nuclera Expands eProtein Discovery Capabilities to Enable Membrane Protein Production
Membrane proteins synthesized and purified within 48 hours. Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized CAMBRIDGE, England & BOSTON, April 14, 2025--(BUSINESS WIRE)--Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the addition of a new membrane protein workflow to its system. This expanded capability enables the expression, purification and stabilization of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free protein synthesis, digital microfluidics, and optimized additive screening, eProtein Discovery can express and purify functional, correctly folded membrane proteins, in 48 hours. Membrane proteins play vital roles in regulating cellular processes and many are implicated in the development and progression of disease. 60% of FDA-approved drugs target membrane proteins1 yet the extraction and stabilization of these structurally complex proteins remains challenging due to their intrinsic hydrophobic nature. Nuclera demonstrated the capabilities of eProtein Discovery to produce membrane proteins by synthesizing MsbA (a membrane transporter) and ZMPSTE24 (an integral membrane protein)2. In 24 hours, eProtein Discovery evaluated different expression and purification conditions, including assessing the effects of using nanodiscs, lipids and detergents, to identify the optimal conditions for producing soluble, stable MsbA and ZMPSTE24. Scale-up production of these membrane proteins was achieved within 48 hours, enabling rapid functional evaluation. MsbA and ZMPSTE24 generated using eProtein Discovery had high-yield, were functionally active, and compatible with cryo-Electron Microscopy (cryo-EM). Existing eProtein Discovery users can access this new membrane protein production capability through a software update. Dr Toby Ost, SVP of Product Development, Nuclera, said: "Membrane protein production has long been a technical challenge, often resulting in misfolded or inactive proteins. eProtein Discovery overcomes these challenges, enabling scientists to rapidly produce functional membrane proteins, accelerating drug discovery and structural biology workflows." Dr Konstantinos Beis, Reader in Membrane Protein Structural Biology, Imperial College London, added: "The eProtein Discovery System is a welcome new toolkit for membrane protein production. We were commissioned via Imperial Consultants to test the protein quality in our lab - and the early results are promising." For more information about Nuclera's eProtein Discovery system, please visit: Paper: How many drug targets are there? Poster: Functional Membrane Proteins - Ready in 48 Hours View source version on Contacts Media contact: Dr Ben RutterZyme CommunicationsTel: +44(0)7920 770 935Email: Sign in to access your portfolio
